Apremilast, a novel oral PDE4 inhibitor approved for psoriasis and psoriasis arthritis, has been shown to inhibit TNF-α production from RA-FLSs, reduce RA-FLSs migration and invasion into cartilage, and ameliorate experimental arthritis models7, 8. This evidence concerns the gene TNF and rheumatoid arthritis.